A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 223,400 shares of FULC stock, worth $1.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
223,400
Holding current value
$1.38 Million
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $1.5 Million - $2.68 Million
223,400 New
223,400 $2.11 Million
Q2 2023

Aug 14, 2023

SELL
$2.26 - $3.8 $1.68 Million - $2.83 Million
-743,704 Reduced 28.13%
1,899,968 $6.27 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $7.48 Million - $37 Million
2,643,672 New
2,643,672 $7.53 Million
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $2.43 Million - $4.5 Million
-494,797 Reduced 24.88%
1,494,003 $12.1 Million
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $6.99 Million - $39.9 Million
1,663,800 Added 511.94%
1,988,800 $9.75 Million
Q1 2022

May 16, 2022

SELL
$9.96 - $23.65 $1.8 Million - $4.27 Million
-180,655 Reduced 35.73%
325,000 $7.69 Million
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $5.12 Million - $10.4 Million
365,655 Added 261.18%
505,655 $8.95 Million
Q3 2021

Nov 15, 2021

SELL
$7.28 - $30.97 $3.01 Million - $12.8 Million
-412,885 Reduced 74.68%
140,000 $3.95 Million
Q2 2021

Aug 16, 2021

SELL
$8.09 - $12.0 $180,900 - $268,332
-22,361 Reduced 3.89%
552,885 $5.79 Million
Q1 2021

May 17, 2021

SELL
$10.94 - $15.32 $8.35 Million - $11.7 Million
-762,877 Reduced 57.01%
575,246 $6.78 Million
Q4 2020

Feb 16, 2021

SELL
$7.84 - $13.4 $1.35 Million - $2.3 Million
-171,877 Reduced 11.38%
1,338,123 $15.7 Million
Q3 2020

Nov 16, 2020

BUY
$7.22 - $20.7 $9.02 Million - $25.9 Million
1,249,303 Added 479.22%
1,510,000 $12 Million
Q2 2020

Aug 14, 2020

BUY
$9.11 - $22.06 $2.37 Million - $5.75 Million
260,697 New
260,697 $4.77 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $322M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.